Chimeric Therapeutics (ASX:CHM) Pre-Tax Income : A$-11.39 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Chimeric Therapeutics's pretax income for the six months ended in Dec. 2023 was A$2.37 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was A$-11.39 Mil. Chimeric Therapeutics's pretax margin was %.

Chimeric Therapeutics Pre-Tax Income Historical Data

The historical data trend for Chimeric Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Pre-Tax Income Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Pre-Tax Income

-15.11

-15.74

-25.41

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial			-9.69	-6.05	-11.64	-13.76	2.37

Competitive Comparison of Chimeric Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Chimeric Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's Pre-Tax Income falls into.

Chimeric Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Chimeric Therapeutics's Pretax Income for the fiscal year that ended in Jun. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-29.487	+	4.826	+	-0.774	+	0.028	+	-0.0010000000000012
	=	-25.41

Chimeric Therapeutics's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-9.039	+	11.693	+	-0.332	+	0.048	+	0.0010000000000008
	=	2.37

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-11.39 Mil.

Chimeric Therapeutics (ASX:CHM) Pre-Tax Income Explanation

Chimeric Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	2.371	/	0
	=	%

Chimeric Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines